BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2021

Feb 23, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2021-02-19

Reporting Person: Babu Yarlagadda S (Senior VP - Drug Discovery)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-19	Common Stock	M	50000	$4.15	Acquired	205587	Direct
2021-02-19	Common Stock	F	22431	$11.53	Disposed	183156	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-19	Stock Option (Right to Buy)	$4.15	M	50000	Disposed	2021-03-01	Common Stock (50000)	Direct

Footnotes

F1: Shares of Common Stock delivered to the Company to satisfy payment of exercise price and tax withholding in connection with stock option exercise.